---
title: "Hong Kong Stock Movement: PEGBIO CO-B surged 23.15%, with clear capital flow; what is stirring the market sentiment?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286728459.md"
description: "PEGBIO CO-B surged 23.15%; CanSino Biologics fell 5.99%, with a transaction volume of HKD 996 million; Innovent Biologics fell 1.83%, with a transaction volume of HKD 970 million; Kelun-Biotech fell 2.89%, with a transaction volume of HKD 440 million; BeiGene fell 2.45%, with a market capitalization of HKD 269.7 billion"
datetime: "2026-05-18T07:11:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286728459.md)
  - [en](https://longbridge.com/en/news/286728459.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286728459.md)
---

# Hong Kong Stock Movement: PEGBIO CO-B surged 23.15%, with clear capital flow; what is stirring the market sentiment?

**Hong Kong Stock Movement**

PEGBIO CO-B surged 23.15%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Stocks with High Trading Volume in the Industry**

Kangfang Biotech fell 5.99%, with a trading volume of HKD 996 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Innovent Biologics fell 1.83%. Based on recent key news:

1.  On May 15, Innovent Biologics signed a strategic cooperation agreement with Tianjin Medical University, focusing on scientific research innovation and achievement transformation in major disease fields. This move may enhance the company's competitiveness in related fields, but it has not boosted the stock price in the short term.
    
2.  On May 15, the National Healthcare Security Administration announced comprehensive regulation of the pharmaceutical retail industry, which may affect Innovent Biologics' market sales strategy, leading to pressure on the stock price. The pharmaceutical industry is facing regulatory pressure, and capital outflow is evident.
    

Kelun-Biotech fell 2.89%, with a trading volume of HKD 440 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Stocks with High Market Capitalization in the Industry**

BeiGene fell 2.45%. Based on recent news,

1.  On May 18, BeiGene provided a new growth curve for Tislelizumab and other early pipelines in the solid tumor field. Although the hematology business can contribute stable cash flow, the competition in the solid tumor track is fierce, affecting the stock price decline. Source: Radar Finance
    
2.  On May 15, Innovent Biologics plans to accelerate the layout of new technology platforms such as ADC and molecular glue, promoting high-quality development of innovative drugs and medical devices, with industry policy dividends affecting BeiGene's stock price. Source: Radar Finance
    
3.  On May 15, Heng Rui Medicine mentioned in its annual report that the sales revenue of innovative drugs continues to grow, while the proportion of generic drug revenue decreases, with intensified industry competition affecting BeiGene's stock price. Source: Radar Finance. The competition in the innovative drug industry is intensifying, and policy dividends are emerging

### Related Stocks

- [02565.HK](https://longbridge.com/en/quote/02565.HK.md)
- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [06990.HK](https://longbridge.com/en/quote/06990.HK.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)

## Related News & Research

- [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)
- [Trump administration expects to strip hundreds at US health agencies of job protections](https://longbridge.com/en/news/286681803.md)
- [Tencent Music completes $2.6 billion acquisition of podcast platform Ximalaya](https://longbridge.com/en/news/286841981.md)
- [ROI-Sulfur squeeze piles more pressure on Indonesian nickel sector: Andy Home](https://longbridge.com/en/news/286434529.md)
- [SCORE Act pulled from House floor after CBC opposition](https://longbridge.com/en/news/286925702.md)